Search For

Fibroblast growth factor 21 in metabolic dysfunction-associated steatotic liver disease and beyond: from bench to bedside

Relationship between transarterial chemoembolization treatment frequency and prognosis in hepatocellular carcinoma patients

Pseudocirrhosis: pathophysiology, clinical mimics, and its role in hepatocellular carcinoma diagnosis and management

Clinical applications and advances in noninvasive prognostic assessment of metabolic dysfunction-associated steatotic liver disease

From platforms to pathways: imaging innovation, quantitative biomarkers, and clinical translation in hepatocellular carcinoma

When a hazard ratio is not enough: non-proportional hazards are reshaping the interpretation of phase III trials in hepatocellular carcinoma

Rewiring neurotrophic signaling to escape targeted therapy in hepatocellular carcinoma

Malnutrition in MASLD-related hepatocellular carcinoma: assessment limitations, multidimensional mechanisms, and microbiome-based interventions

Synergistic era: practice and reflection on TACE combined with systemic therapy in hepatocellular carcinoma

Multidisciplinary management of HCC

From algorithm to dialogue: interpreting the 2026 BCLC-CUSE strategy for HCC care

Precision medicine in metabolic dysfunction-associated steatotic liver disease: genetics, epigenetics, and emerging therapies